U.S. President Donald Trump expressed confidence on Wednesday that China will soon impose the death penalty for fentanyl manufacturing and trafficking, signaling renewed optimism for a bilateral crackdown on the opioid crisis. Speaking ahead of signing the HALT Fentanyl Act, Trump emphasized collaboration with Beijing to halt the flow of synthetic opioids, which have claimed over 450,000 American lives in the past decade.
Fentanyl, a powerful synthetic opioid, remains a top cause of overdose deaths in the U.S., and Washington continues to pressure Beijing to tighten control over precursor chemicals exported from China. Trump’s remarks follow a series of recent moves aimed at reining in the deadly drug trade, including the February imposition of 20% tariffs on Chinese goods linked to fentanyl-related issues.
“I think China’s going to go from doing nothing to issuing the death penalty for those producing fentanyl and sending it here,” Trump told reporters. He added that talks with Chinese leader Xi Jinping were progressing and that Beijing was taking “big steps” in response.
In recent weeks, China has added two more fentanyl precursors—4-piperidone and 1-boc-4-piperidone—to its list of controlled substances. Authorities have also ramped up enforcement, seizing over 2 tons of drugs and arresting 262 individuals for trafficking. Over 1,300 prosecutions and 700 arrests for drug-related money laundering have been reported this year, showing a 2.1% increase from last year.
China, however, has pushed back on U.S. demands to publicize its efforts prominently and has accused Washington of politicizing the fentanyl issue. Still, Trump’s latest remarks suggest a possible breakthrough in cooperation as both nations grapple with rising overdose deaths and escalating tensions.


Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nighttime Shelling Causes Serious Damage in Russia’s Belgorod Region Near Ukraine Border
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Faith Leaders Arrested on Capitol Hill During Protest Against Trump Immigration Policies and ICE Funding
Federal Judge Blocks Trump Administration Move to End TPS for Haitian Immigrants
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Paul Atkins Emphasizes Global Regulatory Cooperation at Fintech Conference
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Iran–U.S. Nuclear Talks in Oman Face Major Hurdles Amid Rising Regional Tensions
Marco Rubio Steps Down as Acting U.S. Archivist Amid Federal Law Limits
Trump Signs “America First Arms Transfer Strategy” to Prioritize U.S. Weapons Sales
Ukraine-Russia Talks Yield Major POW Swap as U.S. Pushes for Path to Peace
Ohio Man Indicted for Alleged Threat Against Vice President JD Vance, Faces Additional Federal Charges
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



